

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A P2X7 purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis; in mammals including man characterised in that wherein the antagonist is selected among from the group consisting of Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP or and HMA.
2. (Currently Amended) The P2X7 purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with of claim 1, characterised in that wherein the antagonist is o-ATP.
3. (Currently Amended) A method for preparing Use of an antagonist of P2X7- purinergic receptors in the preparation of a drug for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis; in mammals, including man characterised in that which method comprises incorporating in said drug an effective amount of a P2X7 purinergic receptor antagonist, wherein the antagonist is selected from the group consisting of among Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP or and HMA.
4. (Currently Amended) The method of Use of an antagonist of P2X7 purinergic receptors in accordance with claim 3 characterised in that wherein the antagonist is o-ATP.
5. (Currently Amended) A pharmaceutical composition which comprises at least one P2X7 purinergic receptor antagonist and at least one pharmaceutically acceptable excipient, wherein the characterised in that antagonist is selected among from the group consisting of Evans Blue, NF279, BBG, o-ATP, KN62, TNP-ATP or and HMA. .

6. (Currently Amended) The A pharmaceutical composition in accordance with of claim 5,
7. characterised in that wherein the antagonist is o-ATP.

Add the following new claims:

8. (New) The P2X7 purinergic receptor antagonist of claim 1, wherein the disease is multiple sclerosis.

9. (New) The method of claim 3, wherein the disease is multiple sclerosis.